Kemudin (Ceftriaxone)

Ceftriaxone exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall. This blocks the transpeptidation step of peptidoglycan synthesis, weakening the wall and causing cell lysis. Its high affinity for multiple PBPs and resistance to many β‑lactamases give it activity against a wide range of Gram‑negative and some Gram‑positive organisms.

The dose of Kemudin is determined by the prescribing clinician based on the type and severity of infection, patient weight, age, and renal or hepatic function. Typical regimens range from a single 1‑gram dose for uncomplicated gonorrhea to 1‑2 grams once daily for severe systemic infections, but exact dosing must follow the prescriber’s order.

Safety data for ceftriaxone in pregnancy are limited, and the drug is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, as small amounts may be excreted in milk; a risk‑benefit assessment is recommended.

To order Kemudin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and assist with import documentation.

Kemudin (ceftriaxiv) offers once‑daily dosing and a broad spectrum that includes many resistant Gram‑negative organisms, distinguishing it from earlier‑generation cephalosporins and many penicillins that often require multiple daily doses. Compared with cefotaxime, another third‑generation cephalosporin, ceftriaxone has a longer half‑life, allowing more convenient dosing schedules.

Kemudin should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If a short period at controlled room temperature is unavoidable, keep the product in its original packaging and use it within the time frame specified by the manufacturer.

Kemudin is supplied as a sterile powder for reconstitution and is administered intravenously. The reconstituted solution is typically diluted in compatible IV fluids and infused over 30 minutes to 2 hours, depending on the clinical situation. Administration must follow aseptic technique and institutional infusion protocols.

The most serious adverse reactions include anaphylaxis, Stevens‑Johnson syndrome, hemolytic anemia, and Clostridioides difficile‑associated colitis. Clinicians should monitor patients for signs of severe hypersensitivity, skin blistering, unexplained anemia, or persistent diarrhea, and discontinue the drug immediately if any of these occur.

Kemudin is contraindicated in patients with a known severe hypersensitivity to ceftriaxone, other cephalosporins, or any component of the formulation. Caution is also required in neonates (≤28 days) receiving calcium‑containing solutions due to the risk of precipitation, and in patients with a history of severe allergic reactions to β‑lactam antibiotics.